BS. Science: University of Kashmir. 1991
MS. Biochemistry: Department of Biochemistry, University of Kashmir 1995
PhD in Experimental Medicine & Biotechnology: Post Graduate Institute of Medical Education and Research, Chandigarh. 2000
Worked as professor and course director for Biochemistry (MS502) and Human Genetics (MS504) for the MBS program at GCSOM, Doylestown campus since 2017. Professor for cancer Genomics and applications of genomics in health and disease course (GN704) at University of Sciences, Philadelphia. Subjects of interest: Biochemistry, Molecular Biology, Human Genetics, Cancer Genetics, Immunology.
View Dr. Sayeed’s publications on Google Scholar.
Dr. Aejaz Sayeed is a seasoned biotechnology executive, translational scientist, and cancer biologist with more than 25 years of experience in precision medicine, biomarker discovery, assay development, liquid biopsy platforms, and oncology product development. He serves as Chief Scientific Officer of CIRNA Diagnostics and Associate Professor at the Baruch S. Blumberg Institute, where he has built and led multidisciplinary research and development programs focused on biomarker discovery and innovative diagnostic technologies, including a circulating RNA (ctRNA)-based liquid biopsy platform for cancer detection and monitoring.
Dr. Sayeed has a proven track record of advancing innovative technologies from concept and intellectual property generation through analytical and clinical validation, pharmaceutical partnerships, and commercial licensing. Under his leadership, CIRNA’s ctRNA technology advanced to a licensing agreement with Hepion, and the company secured strategic funding, including a $400,000 Commonwealth of Pennsylvania Qualified Business Angel Investment award. He has also established and led collaborations with pharmaceutical, biotechnology, and academic partners to advance diagnostic, therapeutic, regenerative medicine, and medical device development programs.
Recognized for his expertise in oncology and liver cancer research, Dr. Sayeed serves as a reviewer for NIH/NCI scientific review panels and leading peer-reviewed journals. He has authored more than 25 peer-reviewed scientific publications, with over 1,125 citations, an h-index of 16, and an i10-index of 17. His work has fostered collaborations with leading academic and healthcare institutions.
Combining scientific innovation with business strategy, Dr. Sayeed excels at building strategic partnerships, leading cross-functional teams, securing research and commercial funding, and translating scientific discoveries into commercially viable products. His work is driven by a commitment to advancing precision medicine and developing innovative technologies that improve cancer detection, disease monitoring, and patient outcomes.
Clinical and translational scientist with more than 25 years of experience leading oncology research, biomarker-driven clinical studies, translational medicine programs, and molecular diagnostics development. Extensive expertise in designing and executing patient-centered research studies, developing biomarker strategies, leading multidisciplinary collaborations, analyzing clinical and molecular datasets, and translating scientific findings into actionable clinical development strategies. Proven track record of collaborating across academic, biotechnology, pharmaceutical, and clinical teams to advance innovative oncology programs from early discovery through clinical validation and implementation, with a focus on precision medicine, biomarker-guided decision-making, and improving patient outcomes.